About ACT Genomics
ACT Genomics is a company based in Taipei (Taiwan) founded in 2014 by Joe Hsueh and Shu Jen Chen was acquired by Delta Electronics in June 2025.. ACT Genomics has raised $20.5 million across 4 funding rounds from investors including Prenetics, Delta Electronics and CLSA Capital Partners. ACT Genomics has completed 1 acquisition, including MC Diagnostics. ACT Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Taipei, Taiwan
- Founders Joe Hsueh, Shu Jen Chen
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.5 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Prenetics
& 9 more
-
Employee Count
Employee Count
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
CTO Team
1 people
CSO Team
1 people
Finance and Accounting
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of ACT Genomics
ACT Genomics has successfully raised a total of $20.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(13 Feb 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series B - ACT Genomics | Valuation | Kyoto University Innovation Capital , Aflac Innovation Partners |
|
| Sep, 2018 | Amount | Series B - ACT Genomics | Valuation | CLSA Capital Partners |
|
| May, 2016 | Amount | Series B - ACT Genomics | Valuation | Hotung Investment Holdings , CDIB Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ACT Genomics
ACT Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Prenetics, Delta Electronics and CLSA Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in university research startups.
|
Founded Year | Domain | Location | |
|
Investments in early to late-stage tech startups are managed.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on AI, IoT, cloud, agriculture, healthcare, biotech, e-commerce, and multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ACT Genomics
ACT Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include MC Diagnostics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics automation systems
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ACT Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Act Genomics Comparisons
Competitors of ACT Genomics
ACT Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Act Genomics
Frequently Asked Questions about ACT Genomics
When was ACT Genomics founded?
ACT Genomics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is ACT Genomics located?
ACT Genomics is headquartered in Taipei, Taiwan.
Is ACT Genomics a funded company?
ACT Genomics is a funded company, having raised a total of $20.5M across 4 funding rounds to date. The company's 1st funding round was a Series B of $12.5M, raised on Feb 13, 2015.
What does ACT Genomics do?
ACT Genomics was founded in 2014 in Taipei, Taiwan, focusing on the genomics sector for cancer applications. Clinical services include next-generation sequencing panels such as ACTImmune for auto-immune diseases, ACTColon for colon cancer, ACTGastric for gastric cancer, and ACTBreast for breast cancer. Pharmacogenomic panels like ACTDrug and ACTOnco are utilized to guide therapy based on patient genotypes. Custom genomic solutions are also extended to biopharma firms and research entities.
Who are the top competitors of ACT Genomics?
ACT Genomics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
How many acquisitions has ACT Genomics made?
ACT Genomics has made 1 acquisition, including MC Diagnostics.
Who are ACT Genomics's investors?
ACT Genomics has 10 investors. Key investors include Prenetics, Delta Electronics, CLSA Capital Partners, Hotung Investment Holdings, and Hua Nan Financial Holdings.